Alopecia – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Alopecia Areata (US)
Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by the targeting of anagen hair follicles by the host immune system, resulting in varying degrees of hair loss. Topical / intralesional corticosteroids and topical or contact immunotherapy are mainstay treatments for AA. In mid 2022, the first therapy gained FDA approval for the treatment of AA: Eli Lilly’s JAK inhibitor Olumiant (baricitinib); two other JAK inhibitors—Pfizer’s Xeljanz (tofacitinib) and Incyte’s Jakafi (ruxolitinib [oral])—are also prescribed off-label for AA, albeit infrequently. As the U.S. AA current treatment landscape continues to evolve, this report offers insights, informed by patient-level claims data, into prescribing trends in AA to help current and future players better understand existing treatment practices in AA and to define the market niche for emerging products.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed AA patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed AA patients?
- In addition to corticosteroids, how are other key drugs and drug classes integrated into the treatment algorithm, and what are their source of business? To what extent are JAK inhibitors (e.g., Olumiant) used for AA?
- What percentage of AA patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of AA patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key drugs: Contact allergens, corticosteroids, cyclosporine A, finasteride, Jakafi, methotrexate, Olumiant, pimecrolimus, retinoids, tacrolimus (topical), Xeljanz
SOLUTION ENHANCEMENT
The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.
Naomi López Caraballo, Ph.D., Healthcare Research & Data Analyst, Infectious, Niche, and Rare Diseases. Dr. López Caraballo is a healthcare research and data analyst for the rare disorders therapy market. She holds a Ph.D. in neuroscience and physiology from the New York University School of Medicine and a B.S. in industrial biotechnology from the University of Puerto Rico in Mayaguez.